Physician profile
Michael E Kelly
NPI 1730330861
$6,552.33
in general payments reported to CMS, 2019-2025
10 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,676 · 2021: $14.92 · 2022: $67.60 · 2023: $145 · 2024: $208 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $5,944.25 | 2019-2024 | Floseal |
| Kerecis Limited | $292.71 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Hemosonics LLC | $108.85 | 2024-2025 | Qunatra Qplus System, Quantra Qplus System |
| Kci USA, INC. | $72.74 | 2023 | Abthera Advance |
| Acera Surgical, INC. | $34.87 | 2024 | Restrata Wound Matrix |
| Integra Lifesciences Corporation | $30.43 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Davol INC. | $23.98 | 2025 | Phasix Mesh |
| Solventum Corporation | $15.25 | 2025 | V.A.C. Granufoam, Abthera, V.A.C. Veraflo |
| Smith+Nephew, INC. | $14.92 | 2021 | |
| Abbott Laboratories | $14.33 | 2025 | Alinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.